JP6455947B2 - ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体 - Google Patents

ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体 Download PDF

Info

Publication number
JP6455947B2
JP6455947B2 JP2016568435A JP2016568435A JP6455947B2 JP 6455947 B2 JP6455947 B2 JP 6455947B2 JP 2016568435 A JP2016568435 A JP 2016568435A JP 2016568435 A JP2016568435 A JP 2016568435A JP 6455947 B2 JP6455947 B2 JP 6455947B2
Authority
JP
Japan
Prior art keywords
dimethyl
triazolo
compound
compound according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016568435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521364A5 (enExample
JP2017521364A (ja
Inventor
モシチンスキ−ペトコフスキ，ラファウ
ボヤルスキ，ウーカシュ
ヴィエチョレク，マチェイ
マイヤー，ヤクブ
ヤノフスカ，シルヴィア
マトロカ，ミコワイ
ボルコフスカ，マウゴジャタ
ステファニアク，フィリプ
ラムパルスカ−プシビシ，モニカ
デュビエル，クシシュトフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma SA
Original Assignee
Celon Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma SA filed Critical Celon Pharma SA
Publication of JP2017521364A publication Critical patent/JP2017521364A/ja
Publication of JP2017521364A5 publication Critical patent/JP2017521364A5/ja
Application granted granted Critical
Publication of JP6455947B2 publication Critical patent/JP6455947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
JP2016568435A 2014-05-19 2015-05-14 ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体 Active JP6455947B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.408251 2014-05-19
PL408251A PL408251A1 (pl) 2014-05-19 2014-05-19 Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
PCT/IB2015/053549 WO2015177688A1 (en) 2014-05-19 2015-05-14 Fused triazole derivatives as phosphodiesterase 10a inhibitors

Publications (3)

Publication Number Publication Date
JP2017521364A JP2017521364A (ja) 2017-08-03
JP2017521364A5 JP2017521364A5 (enExample) 2018-06-21
JP6455947B2 true JP6455947B2 (ja) 2019-01-23

Family

ID=53434395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568435A Active JP6455947B2 (ja) 2014-05-19 2015-05-14 ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体

Country Status (17)

Country Link
US (1) US10138245B2 (enExample)
EP (1) EP3145930B1 (enExample)
JP (1) JP6455947B2 (enExample)
KR (1) KR102404650B1 (enExample)
CN (1) CN106459060B (enExample)
AU (1) AU2015263013B2 (enExample)
CA (1) CA2946258C (enExample)
DK (1) DK3145930T3 (enExample)
EA (1) EA030330B9 (enExample)
ES (1) ES2688084T3 (enExample)
HR (1) HRP20181027T1 (enExample)
HU (1) HUE039847T2 (enExample)
MX (1) MX367647B (enExample)
PL (2) PL408251A1 (enExample)
PT (1) PT3145930T (enExample)
SI (1) SI3145930T1 (enExample)
WO (1) WO2015177688A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017007301A1 (en) * 2015-07-06 2017-01-12 Universiti Sains Malaysia Compound and method for inhibiting sirtuin activities
KR102587382B1 (ko) * 2016-04-29 2023-10-12 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
CN111410657B (zh) * 2019-01-08 2024-05-21 北京鼎材科技有限公司 一种发光材料及其应用
WO2025160629A1 (en) * 2024-01-31 2025-08-07 Certa Therapeutics Pty Ltd Proton sensing gpcr modulators
WO2025178973A1 (en) * 2024-02-20 2025-08-28 Iambic Therapeutics, Inc. Solid state forms of her2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053168A1 (en) * 2007-07-17 2009-02-26 Richard Rickles Treatments of b-cell proliferative disorders
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10

Also Published As

Publication number Publication date
PL408251A1 (pl) 2015-11-23
AU2015263013B2 (en) 2018-10-04
WO2015177688A1 (en) 2015-11-26
AU2015263013A1 (en) 2016-11-17
PT3145930T (pt) 2018-10-11
EP3145930A1 (en) 2017-03-29
EA030330B1 (ru) 2018-07-31
EA030330B9 (ru) 2018-09-28
MX2016015180A (es) 2017-03-23
HRP20181027T1 (hr) 2018-08-24
KR20170005860A (ko) 2017-01-16
SI3145930T1 (sl) 2018-10-30
CA2946258A1 (en) 2015-11-26
HUE039847T2 (hu) 2019-02-28
JP2017521364A (ja) 2017-08-03
DK3145930T3 (en) 2018-09-24
CA2946258C (en) 2023-06-06
EP3145930B1 (en) 2018-07-04
CN106459060A (zh) 2017-02-22
ES2688084T3 (es) 2018-10-30
US10138245B2 (en) 2018-11-27
US20170114064A1 (en) 2017-04-27
KR102404650B1 (ko) 2022-06-02
PL3145930T3 (pl) 2018-11-30
CN106459060B (zh) 2019-04-05
EA201692264A1 (ru) 2017-04-28
MX367647B (es) 2019-08-29

Similar Documents

Publication Publication Date Title
JP6455947B2 (ja) ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体
JP6982343B2 (ja) 治療用阻害化合物
KR102680164B1 (ko) Rock 억제제로서의 페닐아세트아미드
US10308637B2 (en) Therapeutic inhibitory compounds
US9862707B2 (en) TrkA kinase inhibitors, compositions and methods thereof
US8975276B2 (en) Inhibitors of PDE10
JP6564406B2 (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
CN102131800A (zh) 5元和6元杂环化合物
EA020715B1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
CA3219925A1 (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
RS54529B1 (sr) Fenoksimetil heterociklična jedinjenja
US10195201B2 (en) Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
BR112016027023B1 (pt) Derivados de triazol fundidos como inibidores de fosfodiesterase 10a
WO2025113625A1 (zh) 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用
TW202506660A (zh) Mrgprx2拮抗劑及其使用方法
JPWO2000034277A1 (ja) スルホンアミド化合物およびその医薬用途
HK1177739A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
HK1177739B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181214

R150 Certificate of patent or registration of utility model

Ref document number: 6455947

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250